SCNI 📈 Scinai Immunotherapeutics - Overview
Exchange: NASDAQ • Country: Israel • Currency: USD • Type: Common Stock •
SCNI: Vaccines, Antibodies, Therapies, Medicines, Treatments, Products
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel. Web URL: https://www.scinai.com
Additional Sources for SCNI Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
SCNI Stock Overview
| Market Cap in USD | 3m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Semiconductor Materials & Equipment |
| IPO / Inception | 2015-05-12 |
SCNI Stock Ratings
| Growth 5y | -96.8% |
| Fundamental | - |
| Dividend | - |
| Rel. Strength Industry | -343 |
| Analysts | 5/5 |
| Fair Price Momentum | 1.19 USD |
| Fair Price DCF | - |
SCNI Dividends
No Dividends PaidSCNI Growth Ratios
| Growth Correlation 3m | -68.5% |
| Growth Correlation 12m | -81.4% |
| Growth Correlation 5y | -98.5% |
| CAGR 5y | -65.99% |
| CAGR/Mean DD 5y | -0.78 |
| Sharpe Ratio 12m | -0.03 |
| Alpha | -86.12 |
| Beta | 1.46 |
| Volatility | 80.15% |
| Current Volume | 5.6k |
| Average Volume 20d | 11.9k |
What is the price of SCNI stocks?
As of December 22, 2024, the stock is trading at USD 3.40 with a total of 5,552 shares traded.
Over the past week, the price has changed by +0.00%, over one month by +22.55%, over three months by -6.65% and over the past year by -51.86%.
As of December 22, 2024, the stock is trading at USD 3.40 with a total of 5,552 shares traded.
Over the past week, the price has changed by +0.00%, over one month by +22.55%, over three months by -6.65% and over the past year by -51.86%.
Is Scinai Immunotherapeutics a good stock to buy?
No, based on ValueRay Analyses, Scinai Immunotherapeutics (NASDAQ:SCNI) is currently (December 2024) a stock to sell. It has a ValueRay Growth Rating of -96.78 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SCNI as of December 2024 is 1.19. This means that SCNI is currently overvalued and has a potential downside of -65%.
No, based on ValueRay Analyses, Scinai Immunotherapeutics (NASDAQ:SCNI) is currently (December 2024) a stock to sell. It has a ValueRay Growth Rating of -96.78 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SCNI as of December 2024 is 1.19. This means that SCNI is currently overvalued and has a potential downside of -65%.
Is SCNI a buy, sell or hold?
Scinai Immunotherapeutics has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy SCNI.
Scinai Immunotherapeutics has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy SCNI.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for SCNI stock price target?
According to ValueRays Forecast Model, SCNI Scinai Immunotherapeutics will be worth about 1.4 in December 2025. The stock is currently trading at 3.40. This means that the stock has a potential downside of -60.29%.
According to ValueRays Forecast Model, SCNI Scinai Immunotherapeutics will be worth about 1.4 in December 2025. The stock is currently trading at 3.40. This means that the stock has a potential downside of -60.29%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 700 | 20488.2% |
| Analysts Target Price | 39 | 1047.1% |
| ValueRay Target Price | 1.4 | -60.3% |